0.66
+0.0475(+7.72%)
Currency In USD
Address
1167 Massachusetts Avenue
Arlington, MA 02476
United States of America
Phone
781 996 5252
Website
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
38
First IPO Date
January 29, 2018
| Name | Title | Pay | Year Born |
| David Elliot Lazar | Chairman & Chief Executive Officer | 1.01M | 1991 |
| R. Kim Brazzell | Head of R&D and Chief Medical Officer | 703,644 | 1953 |
| Todd Bazemore | Principal Executive Officer & Director | 732,507 | 1970 |
| Francis S. Mah | Chief Medical Advisor | 0 | N/A |
| Justin Hanes | Founder & Chair of the Scientific Advisory Board | 0 | N/A |
| Carl Rennie | Executive Director of Account Management | 0 | N/A |
| Darius Kharabi | Chief Business Officer | 0 | 1980 |
| Josiah Craver | Senior VP & Corporate Controller | 0 | N/A |
| Patrick Bedell | Executive Director of Trade & Alternate Channels | 0 | N/A |
| Vincent Kosewski | Senior VP of Manufacturing & Supply Chain Management | 0 | 1963 |
| Jill S. Steier | Executive Director of Investor Relations & Corporation Communications | 0 | N/A |
| Mary Reumuth | Chief Financial Officer, Treasurer & Secretary | 0 | 1975 |
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
